Earnings Releases·Nov 4, 2026, 4:16 PM ET

Bio-Rad Laboratories — Third Quarter 2026 Earnings Summary

Total net sales increased 0.5% year-over-year to $656.4 million, driven by a 2.7% rise in Clinical Diagnostics, while Life Science sales declined 2.8% due to academic market challenges and lower chromatography sales.
GAAP net income surged to $458.6 million ($17.02/share) from a $341.9 million loss in the prior year, primarily due to a $588.2 million gain on the Sartorius AG investment; Non-GAAP net income rose 17.6% to $71.5 million ($2.65/share).
Full-year 2026 non-GAAP revenue guidance is set for a decline of approximately 3.0% to growth of 0.5%, with an estimated operating margin of 10.0% to 12.0%, reflecting progress in transformation and reprioritized R&D.
GAAP results included $49.8 million in impairment charges and significant restructuring costs, while treasury stock purchases totaled $79.3 million for the nine-month period, down from $295.5 million in the same period of 2025.